K-ras mutations in pancreatic ductal proliferative lesions - PubMed (original) (raw)

Comment

. 1994 Dec;145(6):1547-50.

• PMID: 7992857
• PMCID: PMC1887480

Comment

K-ras mutations in pancreatic ductal proliferative lesions

D S Klimstra et al. Am J Pathol. 1994 Dec.

No abstract available

PubMed Disclaimer

Comment on

• Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma.
  DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van den Berg FM, Cameron JL, van Mansfeld AD. DiGiuseppe JA, et al. Am J Pathol. 1994 May;144(5):889-95. Am J Pathol. 1994. PMID: 8178941 Free PMC article.

Similar articles

• K-ras mutation in focal proliferative lesions of human pancreas.
  Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. Terhune PG, et al. Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):515-21. Cancer Epidemiol Biomarkers Prev. 1998. PMID: 9641496
• Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
  Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Caldas C, et al. Cancer Res. 1994 Jul 1;54(13):3568-73. Cancer Res. 1994. PMID: 8012983
• Detection of K-ras point mutation at codon 12 in pancreatic diseases: a study in a Brazilian casuistic.
  Kubrusly MS, Cunha JE, Bacchella T, Abdo EE, Jukemura J, Penteado S, Morioka CY, de Souza LJ, Machado MC. Kubrusly MS, et al. JOP. 2002 Sep;3(5):144-51. JOP. 2002. PMID: 12221329
• Significance of K-ras codon 12 point mutation in pancreatic juice in the diagnosis of carcinoma of the pancreas.
  Kimura W, Zhao B, Futakawa N, Muto T, Makuuchi M. Kimura W, et al. Hepatogastroenterology. 1999 Jan-Feb;46(25):532-9. Hepatogastroenterology. 1999. PMID: 10228857 Review.

Cited by

• Pancreatic cancer stromal biology and therapy.
  Xie D, Xie K. Xie D, et al. Genes Dis. 2015 Jun 1;2(2):133-143. doi: 10.1016/j.gendis.2015.01.002. Genes Dis. 2015. PMID: 26114155 Free PMC article.
• Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer.
  Ji Z, Mei FC, Lory PL, Gilbertson SR, Chen Y, Cheng X. Ji Z, et al. Front Biosci (Landmark Ed). 2009 Jan 1;14(8):2904-10. doi: 10.2741/3421. Front Biosci (Landmark Ed). 2009. PMID: 19273243 Free PMC article.
• A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses.
  Boyd ZS, Raja R, Johnson S, Eberhard DA, Lackner MR. Boyd ZS, et al. J Mol Diagn. 2009 Jul;11(4):290-7. doi: 10.2353/jmoldx.2009.080124. Epub 2009 May 21. J Mol Diagn. 2009. PMID: 19460940 Free PMC article.
• Mechanisms of development and progression of pancreatic neoplasms.
  Furukawa T. Furukawa T. Pathol Int. 2022 Nov;72(11):529-540. doi: 10.1111/pin.13272. Epub 2022 Sep 26. Pathol Int. 2022. PMID: 36161420 Free PMC article. Review.
• Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
  Nissim S, Idos GE, Wu B. Nissim S, et al. Pancreas. 2012 Nov;41(8):1195-205. doi: 10.1097/MPA.0b013e3182580fb4. Pancreas. 2012. PMID: 22750975 Free PMC article.

References

1. 1. Tohoku J Exp Med. 1982 Jun;137(2):115-24 - PubMed
2. 1. Cancer Res. 1976 Jul;36(7 PT 2):2690-8 - PubMed
3. 1. Cancer. 1979 Apr;43(4):1418-28 - PubMed
4. 1. Virchows Arch A Pathol Anat Histol. 1980;387(2):221-33 - PubMed
5. 1. Am J Clin Pathol. 1982 Feb;77(2):137-52 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal